Nearly one in six US Food and Drug Administration (USFDA) inspections at Indian drug manufacturing sites now ends with findings serious enough to warrant regulatory action, according to a new report from India Ratings and Research (Ind-Ra), putting quality compliance back at the centre of the growth debate for Indian pharma exporters.

The ratings agency said about 17 per cent of USFDA inspections of Indian facilities have been classified as Official Action Indicated (OAI), the category the US regulator uses when inspectors identify deficiencies that need further review. Depending on the nature and severity of the observations, an OAI outcome can hold up pending product approvals or lead to restrictions on medicines shipped from the affected plant.

Advertisement

A reversal after a decade of improvement

The latest figure marks a reversal of a long improvement curve. Ind-Ra noted that the OAI share for Indian sites fell from roughly 23 per cent in 2014 to around 11 per cent in 2024, before climbing back to 17 per cent. The rise comes as USFDA inspections in India have become more frequent and increasingly unannounced or short-notice.

Data shared by the USFDA’s India Office earlier this month offers context: in FY25 the regulator inspected 207 Indian facilities and gave 37 of them an OAI classification, broadly in line with the global average of about 18 per cent. The most common deficiencies cited globally included inadequate written records, insufficient investigations and weak laboratory controls, while data integrity, including at outsourced clinical research and bioanalytical providers, remains a recurring concern.

Why it matters for Indian drugmakers

The stakes are high. Ind-Ra said Indian companies supply about 47 per cent of the generic prescriptions dispensed in the US, a market that accounts for 35–38 per cent of India’s pharmaceutical exports and 30–35 per cent of revenue for the companies it rates.

That US revenue is already under pressure. Sales in the US for Ind-Ra-rated companies declined 1.7 per cent year-on-year in FY26, and the fall widened to 5.8 per cent in Q1 FY27, partly because high-margin opportunities such as generic Revlimid (lenalidomide) are normalising as competition grows. The same trend has shown up in the September-quarter results of several large drugmakers this month.

“The US remains strategically important for Indian pharma companies despite geopolitical uncertainty, and generic competition,” the agency said, adding that a tougher inspection environment could delay approvals for some products at a time when pricing pressure and possible trade restrictions are also weighing on the market.

Diversification as a cushion, not a cure

Ind-Ra said companies with a broader product basket and a wider geographic spread are better placed to absorb disruption at any single plant or product. Moving up the value chain into complex generics, specialty products and new launches can also open fresh growth avenues.

The agency cautioned, however, that diversification takes time and capital. Entering new markets needs fresh regulatory approvals, and complex products demand higher R&D spending and technical depth. “Performance will remain company-specific, with product complexity, launch pipelines, competitive intensity, backward integration, and exclusivity opportunities determining growth and margins,” the report said.

The quality imperative

For India’s pharmaceutical manufacturing ecosystem, the report reinforces a familiar message: sustained investment in quality systems, digital batch records, laboratory controls, data integrity and supplier oversight is no longer only a compliance cost but a direct driver of market access. With India operating the largest network of USFDA-approved plants outside the US, consistent inspection outcomes will be central to protecting the country’s position as a trusted global supplier of affordable medicines.

Sources: India Ratings and Research report as reported by Financial Express (26 October 2026); ETPharma coverage of USFDA India Office inspection data (October 2026).

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!